News

Impactful New Science and Advancements in Cancer Care Research Revealed and Discussed at the US Oncology Research 17th Annual Science Forum

October 8, 2018

More than 200 leading cancer researchers gathered to discuss the future of cancer care

THE WOODLANDS, TEXAS, October 8, 2018—US Oncology Research recently held its 17th Annual Science Forum (the Forum) in Denver, bringing together more than 200 leading research physicians and their clinical teams. This year’s agenda included a focus on leading-edge clinical and technological topics, including artificial intelligence, the immunologic bank and new gene treatments like CAR-T cell therapies.

“This meeting brings outstanding new science to help our patients now,” said Daniel Von Hoff, MD, FACP, chief scientific officer, US Oncology Research. “This science will allow earlier diagnosis via artificial intelligence, introduction of new therapeutics with unique mechanisms of action, the maximum harnessing of a person’s immune system to prevent or eliminate cancer, and gene therapy to likely cure diseases we never dreamed we could change.”

Read More

The US Oncology Network Announces Top-Tier MIPS Results

October 4, 2018

Affiliated practices to benefit from high positive payment adjustment

 

THE WOODLANDS, TEXAS, October 4, 2018— The US Oncology Network (The Network) today announced results of the 2017 Merit-based Incentive Payment System (MIPS) for its affiliated practices. Based on the successful implementation of quality improvement, adoption and performance in the first year of MIPS, practices in The Network will receive an average positive payment adjustment of 1.90%*—close to the maximum allowable adjustment of 2.02%*. In addition, 99% of physicians in The Network were in the top tier of performers.

Launched in 2017, MIPS is a bi-partisan government-mandated program that aims to reduce healthcare costs and improve quality. The 2017 results were released by the Centers for Medicare and Medicaid Services (CMS) on June 29, 2018. A clinician’s performance in 2017 will impact their Medicare reimbursement in 2019.

Read More

US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology

August 23, 2018

Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research

THE WOODLANDS, TEXAS, U.S., IRVINE, CALIF., U.S. and AMSTERDAM, NETHERLANDS (August 23, 2018) – Agendia, Inc., a world leader in precision oncology, announced today that US Oncology Research, one of the nation’s largest research networks dedicated to bringing cutting-edge treatment options to cancer patients and consisting of more than 150 research sites and over 1,000 investigators, has joined Agendia’s FLEX breast cancer registry study. FLEX is a large-scale, prospective, observational breast cancer study that links full genome profiling, including Agendia’s MammaPrint® risk of recurrence and BluePrint® molecular subtyping tests, with complete clinical data to create a comprehensive patient database with the potential to identify new gene associations with prognostic and/or predictive value in breast cancer.

Read More

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

August 15, 2018

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer

Read More

Progressive Care Integrates with Illinois Cancer Specialists to Join The US Oncology Network

August 6, 2018

More patients in suburban Chicago will benefit from the combined expertise and resources

Chicago, Illinois (August 6, 2018) – Illinois Cancer Specialists (ICS), an affiliate of The US Oncology Network (The Network), announced today that Progressive Care has joined its practice. The combined practice will continue to offer comprehensive, state-of-the-art cancer care in its nine convenient, patient-friendly community settings throughout suburban Chicago. ICS has been a part of The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices, for several years.

“The Network will benefit greatly from the addition of these experienced oncology care providers,” said Marcus Neubauer, M.D., chief medical officer. “I am looking forward to collaborating with them as part of our larger organization in the Chicago area.”

Read More

The US Oncology Network Promotes Leader in Value-Based Care Dr. Marcus Neubauer to Chief Medical Officer

July 17, 2018

Medical oncologist is appointed to spearhead The Network’s significant medical programs and collaborative, integrated approach to cancer care

The Woodlands, Texas (July 17, 2018) The US Oncology Network (The Network) announced the appointment of Marcus Neubauer, M.D., as its chief medical officer, building on its mission of delivering a comprehensive approach to cancer care. Michael Seiden, M.D., Ph.D. will continue to lead The Network as its president.

Dr. Neubauer has been a practicing medical oncologist for over 20 years, serving previously as a physician and leader in our Kansas City practice. For the past five years he has served as the vice president and medical director for payer, clinical services, and value-based care, working with over 1,400 community oncologists across the country. He is a recognized leader in innovation in clinical pathways, value-based care and contracting and the Center for Medicare and Medicaid Innovation’s (CMMI®) Oncology Care Model.

Read More

The US Oncology Network Welcomes Breast Surgeon Dr. Loren Rourke to a New Role as Chief Surgical Officer

July 9, 2018

Renowned breast surgeon appointed to spearhead The Network’s surgical programs and collaborative, integrated approach to cancer care

The Woodlands, Texas (July 9, 2018) The US Oncology Network (The Network) announced the appointment of Loren Rourke, M.D., M.H.C.M., as its chief surgical officer, a new role created to support and enhance the surgical community within The Network, fortifying its mission of delivering comprehensive approach to cancer care.

Dr. Rourke brings more than 15 years of surgical experience to The US Oncology Network – experience that includes numerous academic appointments, committees, honors, awards and publications. Most recently, she served as regional breast program director at Houston Methodist. Previously, she held such leadership positions as medical director for the Maine Medical Center Cancer Institute Breast Center (Scarborough, ME) and surgical director of St. Luke’s Woodlands breast program.

Read More

Oncologists from The US Oncology Network and US Oncology Research to Present Data from More Than 40 Abstracts During the 54th Annual ASCO Meeting

May 30, 2018

Expansive clinical research and real-world evidence data to be presented on prostate cancer, genome sequencing, melanoma, bladder cancer, metastatic breast cancer and more

The Woodlands, Texas (May 30, 2018) – McKesson Specialty Health announced today that oncologists from The US Oncology Network (The Network) and US Oncology Research will showcase detailed findings from 43 studies during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1–5, 2018, in Chicago with more than 32,000 oncology professionals in attendance. The study abstracts accepted for presentation represent substantial contributions made by community oncologists towards the understanding and advancement of cancer care.

Read More

Real-World Evidence from McKesson Supports First-Ever FDA Approval for Metastatic Merkel Cell Carcinoma Drug

May 16, 2018

Study Wins the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes

The Woodlands, Texas (May 16, 2018) —  A powerful, real-world evidence study designed by McKesson Specialty Health for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease. Recently “Merkel Cell Carcinoma Observational Study for Historic Comparison” received the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes Research, recognizing how data research supports true innovation in oncology care.

The award acknowledges excellence in health economics and outcomes research (HEOR), a strategic focus for the company, and was announced at an award ceremony with organizers Pharma Intelligence, biopharma companies, researchers, and providers last month in Boston.

Read More

Texas Oncology Receives 2018 PBMI Excellence Award for Care Management Strategies

May 7, 2018

Industry Recognition Highlights Texas Oncology’s  Integrated Pharmacy Approach to Attain Better Patient Outcomes and Lower Costs

DALLAS (May 7, 2018) — Texas Oncology, a practice in The US Oncology Network (The Network), received a 2018 Excellence Award from Pharmacy Benefit Management Institute® (PBMI) for its Medically Integrated Pharmacy Management (MIPM) approach to achieve better results in cancer care. The MIPM model includes a team of board-certified oncologists, as well as other healthcare professionals, to deliver patient-focused solutions that drive industry-leading outcomes and contain costs.

Read More

Virginia Cancer Specialists and The US Oncology Network Welcome Breast Surgeon Dr. Hernan Vargas

March 12, 2018

Renowned breast surgeon joins practice with more than two decades of experience, expanding the service offering to more patients

Fairfax, Va. (March 12, 2018) Virginia Cancer Specialists (VCS) announced that Hernan Vargas, MD, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.

Read More

Consultants in Medical Oncology and Hematology Joins The US Oncology Network, Enhancing Its Ability to Deliver High-Quality Care throughout the Greater Philadelphia Area

January 18, 2018

Practice increases clinical trial and advanced treatment options while gaining access to resources that improve operational efficiencies

Philadelphia, Pa. (January 18, 2018) – Consultants in Medical Oncology and Hematology (CMOH), a premier provider of comprehensive medical oncology services throughout the Philadelphia region for nearly 30 years and a national leader in the development of patient and physician-focused value-based cancer care delivery models, has joined The US Oncology Network (The Network). The Network is the largest organization of its kind comprised of community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care.

Read More

iKnowMed EHR and iKnowMed Generation 2 EHR Receive 2015 ONC-ACB Certification

January 5, 2018

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System

Read More

McKesson Specialty Health and US Oncology Research Announce Schedule of Presentations at the 2017 American Society of Hematology Annual Meeting and Exposition

December 4, 2017

19 abstracts on clinical research conducted by top affiliated investigators are scheduled for presentation

The Woodlands, Texas (December 4, 2017) – At the 59th American Society of Hematology Annual Meeting and Exposition (ASH), leading investigators from The US Oncology Network and US Oncology Research will showcase detailed findings from 19 studies (four orals, 14 poster presentations and one e-publication) covering topics such as multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms and more. The 59th ASH Annual Meeting, a premier scientific event in malignant and non-malignant hematology, will be held December 9-12 in Atlanta.

Read More

Virginia Cancer Specialists and The US Oncology Network Welcome Dr. Stephanie Akbari

November 28, 2017

Dr. Akbari, a pioneer in breast cancer surgery, brings new line of treatment services to the clinic

Fairfax, Va. (November 28, 2017) Virginia Cancer Specialists (VCS) announced that Stephanie Akbari, MD, FACS, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.

Read More

Frederick Oncology & Hematology Associates Joins Maryland Oncology Hematology and The US Oncology Network

November 3, 2017

Affiliation enhances care at both practices, expanding Maryland Oncology Hematology’s services into the Baltimore–Washington Metropolitan Area

Read More

US Oncology Research Annual Science Forum Focuses on Advances in Clinical Research, Enabling Promising New Treatments for Patients in the Community Setting

November 2, 2017

Organization celebrates enrolling 70,000 patients to clinical trials, contributing to more than 70 FDA cancer therapy approvals

Read More

Southern Cancer Center is Global Leader in Kidney Cancer Clinical Trial

September 19, 2017

Mobile, Ala. (September 19, 2017) - Southern Cancer Center (SCC), a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients.

This phase 3 clinical trial will look at various investigational combination therapies including an immune checkpoint inhibitor. This is an important trial to gain information on previously untreated advanced or metastatic renal cell carcinoma (RCC).

Read More

US Oncology Research plays an important role in the clinical development for NERLYNX (neratinib) tablets

September 12, 2017

NERLYNXTM is a new treatment option for early-stage HER2+ breast cancer patients following adjuvant trastuzumab-based therapy in the extended adjuvant setting

The Woodlands, Texas (September 12, 2017) — Early-stage breast cancer patients with HER2-positive tumors now have a promising new anti-HER2 treatment option in the extended adjuvant setting, thanks in large part to the efforts and expertise of US Oncology Research and McKesson Specialty Health. US Oncology Research is the pioneering research arm of The US Oncology Network and is supported by McKesson Specialty Health. US Oncology Research played an important pivotal role supporting the drug’s manufacturer, Puma Biotechnology, Inc., through the clinical trial, ExteNET that led to approval by the U.S. Food and Drug Administration (FDA) on July 17, 2017.

Read More

US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations

August 1, 2017

Eligible Patients to be Directed to Epizyme’s Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma

THE WOODLANDS, Texas and CAMBRIDGE, Mass. (August 1, 2017) - Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of independent, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, today announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients with EZH2 mutations. Once identified, eligible candidates will be directed to Epizyme’s ongoing Phase 2 clinical trial of tazemetostat, the Company’s first-in-class EZH2 inhibitor, as a single-agent treatment for relapsed or refractory patients with FL or DLBCL.

Read More

Pages